NEW YORK – Inivata said today that it has signed a distribution agreement with IPS Genomix to provide its InVisionFirst-Lung and InVisionSeq liquid biopsy tests to cancer patients and partners in the Middle East and Africa.
Under the agreement, IPS Genomix — a part of Integrated Pharma Solutions — will facilitate patient access through both insurers and in the private pay market in the United Arab Emirates, Qatar, Kuwait, Bahrain, Lebanon, Jordan, Egypt, and the Kingdom of Saudi Arabia.